Hot Features
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III... RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.049 | -5.01432664756 | 0.9772 | 0.99 | 0.87 | 388372 | 0.92975192 | CS |
| 4 | 0.0166 | 1.82097411145 | 0.9116 | 0.99 | 0.77 | 336962 | 0.89112351 | CS |
| 12 | 0.0982 | 11.8313253012 | 0.83 | 1.3 | 0.77 | 380016 | 0.96229175 | CS |
| 26 | -0.0218 | -2.29473684211 | 0.95 | 1.3 | 0.77 | 307488 | 0.96048697 | CS |
| 52 | -0.4618 | -33.2230215827 | 1.39 | 1.45 | 0.7006 | 341330 | 1.06984473 | CS |
| 156 | -1.1018 | -54.275862069 | 2.03 | 3.29 | 0.5306 | 208137 | 1.42719051 | CS |
| 260 | -7.3218 | -88.7490909091 | 8.25 | 16.74 | 0.5306 | 352953 | 6.01099781 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.